AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

AbbVie Inc.

AbbVie Inc has been upgraded by HSBC to Buy from Hold, with a target price increase to 265 from 225. This report, released approximately six hours...

HSBC upgrades AbbVie to Buy, raising target to 265. Strong growth momentum and pipeline developments drive positive market sentiment.

AbbVie Inc's stock has seen an increase during market hours, moving up since Monday. Conversations on social media highlight recent studies present...

AbbVie Inc's stock rises amid social media buzz on Lilly's Jaypirca, which claims superiority over Imbruvica for chronic lymphoblastic leukaemia. O...

AbbVie Inc is currently experiencing an upward price movement, coinciding with a significant rise in the Biotechnology sub-sector. Targeted deals,...

AbbVie gains traction amid rising biotech sector. Strategic focus on IBD, dermatology, and neuroscience drives investor optimism.

AbbVie Inc is experiencing notable developments as Amneal Pharmaceuticals has received FDA approval for its cyclosporine ophthalmic emulsion 0.05%,...

Amneal gains FDA approval for a generic Restasis, pressuring AbbVie. Meanwhile, AbbVie prepares to present new oncology data at ASH 2025.

AbbVie Inc (ABBV) has seen its stock price decline by 1.2% since Friday. During pre-market hours, social media discussions highlighted advancements...

AbbVie faces pressure from rising competition in CAR-T therapies and antibody-drug conjugates. Regeneron's decline and weak U.S. manufacturing data...

AbbVie Inc. has received a positive reimbursement recommendation from Canada's Drug Agency for its drug SKYRIZI (risankizumab), which treats adults...

AbbVie gains positive reimbursement for SKYRIZI in Canada. Decision supported by clinicians and patient groups, enhancing treatment access for ulce...

CollPlant's CEO, Yehiel Tal, announced a 25% reduction in workforce while emphasizing collaboration with AbbVie on its dermal filler product candid...

CollPlant cuts workforce by 25%, focusing on AbbVie collaboration. Regeneron’s price rise may influence AbbVie’s stock performance.

AbbVie Inc is experiencing a price increase, aligning with the broader market movement. The company has announced the launch of the AbbVie Biotech...

AbbVie launches Biotech Innovators Award for startups. This initiative boosts market confidence, aligning with positive sentiment in biotech.

AbbVie Inc (ABBV) has experienced a notable decline of nearly three percent since Friday. Recent social media conversations have centered on the st...

AbbVie faces market volatility, sparking social media buzz. Discussions highlight a potential breakout above 238.2 amid overall healthcare sector s...

AbbVie Inc is currently experiencing a decline, moving in tandem with the Biotechnology sector, which is also seeing significant downward movement....

AbbVie declines amid broader biotech downturn. FDA approval for EPKINLY treatment may overshadow #ASH25 data presentation.

AbbVie Inc (ABBV) is currently experiencing a price increase, in alignment with a significant upward movement in the Biotechnology sector. The comp...

AbbVie gains as FDA approves EPKINLY for lymphoma. Approval marks first for bispecific combination therapy, boosting biotech sector sentiment.

AbbVie Inc is currently experiencing a modest price increase, moving in tandem with the broader Biotechnology sector, which is also showing signifi...

AbbVie gains as Health Canada approves new LUPRON DEPOT® for advanced prostate cancer. Johnson & Johnson's price rise highlights sector synergy.

AbbVie Inc (ABBV) is currently experiencing a price increase, aligning with a notable upward movement in the Biotechnology sector. The company has...

AbbVie’s stock rises amid strong biotech sector gains. The launch of *Second Winds* underscores its commitment to blood cancer support.

AbbVie Inc (NYSE: ABBV) is currently experiencing an uptick, moving higher alongside the Biotechnology sector. Scotiabank has initiated coverage on...